Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Pharmacology and Therapeutics

Volumn 209, Issue , 2020, Pages

  Shiraki, Kimiyasu ^a   Daikoku, Tohru ^b  

^a SENRI KINRAN UNIVERSITY   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

Antiviral agent; Chain termination; Ebola; Favipiravir; Influenza; Resistant virus

Indexed keywords

ACICLOVIR; FAVIPIRAVIR; OSELTAMIVIR; RNA DIRECTED RNA POLYMERASE; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EBOLA HEMORRHAGIC FEVER; GENE MUTATION; HERPESVIRIDAE; HUMAN; INFLUENZA; INFLUENZA VIRUS; LETHALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PANDEMIC INFLUENZA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA SYNTHESIS; RNA VIRUS INFECTION; SEASONAL INFLUENZA; VIRUS CULTURE; VIRUS GENOME; VIRUS RESISTANCE; ANIMAL; GENETICS; METABOLISM;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN; PYRAZINES; RNA VIRUS INFECTIONS;

EID: 85081688773     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2020.107512     Document Type: Review

References (131)

1. Abdelnabi, R., Jochmans, D., Verbeken, E., Neyts, J., Delang, L., Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. Antiviral Research 149 (2018), 113–117.
2. Abdelnabi, R., Morais, A.T.S., Leyssen, P., Imbert, I., Beaucourt, S., Blanc, H., Delang, L., Understanding the mechanism of the broad-Spectrum antiviral activity of Favipiravir (T-705): Key role of the F1 motif of the viral polymerase. Journal of Virology, 91, 2017 (e00487–17).
3. Aggarwal, S., Bradel-Tretheway, B., Takimoto, T., Dewhurst, S., Kim, B., Biochemical characterization of enzyme fidelity of influenza A virus RNA polymerase complex. PLoS One, 5, 2010, e10372.
4. Akahoshi, Y., Kanda, J., Ohno, A., Komiya, Y., Gomyo, A., Hayakawa, J., Kanda, Y., Acyclovir-resistant herpes simplex virus 1 infection early after allogeneic hematopoietic stem cell transplantation with T-cell depletion. Journal of Infection and Chemotherapy 23 (2017), 485–487.
5. Arias, A., Thorne, L., Goodfellow, I., Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife, 3, 2014, e03679.
6. Bai, C.Q., Mu, J.S., Kargbo, D., Song, Y.B., Niu, W.K., Nie, W.M., Jiang, J.F., Clinical and Virological characteristics of Ebola virus disease patients treated with Favipiravir (T-705)-Sierra Leone, 2014. Clinical Infectious Diseases 63 (2016), 1288–1294.
7. Baker, L., Bat rabies outbreak in Peru claims one, but others survive: Mass vaccination campaign underway. https://rabiesalliance.org/resource/bat-rabies-outbreak-peru-claims-one-others-survive-mass-vaccination-campaign-underway, 2017.
8. Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Govorkova, E.A., T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. Journal of Virology 87 (2013), 3741–3751.
9. Batiuk, T.D., Schnizlein-Bick, C., Plotkin, Z., Dagher, P.C., Guanine nucleosides and Jurkat cell death: Roles of ATP depletion and accumulation of deoxyribonucleotides. American Journal of Physiology. Cell Physiology 281 (2001), C1776–C1784.
10. Beis, I., Newsholme, E.A., The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. The Biochemical Journal 152 (1975), 23–32.
11. Bixler, S.L., Bocan, T.M., Wells, J., Wetzel, K.S., Van Tongeren, S.A., Dong, L., Warren, T.K., Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antiviral Research 151 (2018), 97–104.
12. Cao, B., A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza. NCT03394209 https://clinicaltrials.gov/ct2/show/NCT03394209, 2018.
13. Cardona-Ospina, J.A., Henao-SanMartin, V., Paniz-Mondolfi, A.E., Rodriguez-Morales, A.J., Mortality and fatality due to Chikungunya virus infection in Colombia. Journal of Clinical Virology 70 (2015), 14–15.
14. Caroline, A.L., Powell, D.S., Bethel, L.M., Oury, T.D., Reed, D.S., Hartman, A.L., Broad spectrum antiviral activity of favipiravir (T-705): Protection from highly lethal inhalational Rift Valley fever. PLoS Neglected Tropical Diseases, 8, 2014, e2790.
15. Carrat, F., Vergu, E., Ferguson, N.M., Lemaitre, M., Cauchemez, S., Leach, S., Valleron, A.J., Time lines of infection and disease in human influenza: A review of volunteer challenge studies. American Journal of Epidemiology 167 (2008), 775–785.
16. CDC, C. F. D. C. A. Prevention, (eds.) Influenza Type A Viruses, 2017, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm.
17. Cheung, P.P., Watson, S.J., Choy, K.T., Fun Sia, S., Wong, D.D., Poon, L.L., Yen, H.L., Generation and characterization of influenza A viruses with altered polymerase fidelity. Nature Communications, 5, 2014, 4794.
18. Craig, S.P. 3rd, Eakin, A.E., Purine phosphoribosyltransferases. The Journal of Biological Chemistry 275 (2000), 20231–20234.
19. Daikoku, T., Mizuguchi, M., Obita, T., Yokoyama, T., Yoshida, Y., Takemoto, M., Shiraki, K., Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir. Journal of Microbiology, Immunology, and Infection 51 (2017), 581–586.
20. Daikoku, T., Tannai, H., Honda, M., Onoe, T., Matsuo, K., Onoye, Y., Shiraki, K., Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy. Journal of Dermatological Science 82 (2016), 160–165.
21. Daikoku, T., Yoshida, Y., Okuda, T., Shiraki, K., Characterization of susceptibility variants of influenza virus grown in the presence of T-705. Journal of Pharmacological Sciences 126 (2014), 281–284.
22. Damjanovic, D., Divangahi, M., Kugathasan, K., Small, C.L., Zganiacz, A., Brown, E.G., Xing, Z., Negative regulation of lung inflammation and immunopathology by TNF-alpha during acute influenza infection. The American Journal of Pathology 179 (2011), 2963–2976.
23. Delang, L., Abdelnabi, R., Neyts, J., Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Research 153 (2018), 85–94.
24. Delang, L., Segura Guerrero, N., Tas, A., Querat, G., Pastorino, B., Froeyen, M., Leyssen, P., Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. The Journal of Antimicrobial Chemotherapy 69 (2014), 2770–2784.
25. Dharan, N.J., Gubareva, L.V., Meyer, J.J., Okomo-Adhiambo, M., McClinton, R.C., Marshall, S.A., Fry, A.M., Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 (2009), 1034–1041.
26. Diebold, S.S., Montoya, M., Unger, H., Alexopoulou, L., Roy, P., Haswell, L.E., Reis e Sousa, C., Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424 (2003), 324–328.
27. Doyle, W.J., Skoner, D.P., Hayden, F., Buchman, C.A., Seroky, J.T., Fireman, P., Nasal and otologic effects of experimental influenza A virus infection. The Annals of Otology, Rhinology, and Laryngology 103 (1994), 59–69.
28. Drake, J.W., Rates of spontaneous mutation among RNA viruses. Proceedings of the National Academy of Sciences of the United States of America 90 (1993), 4171–4175.
29. Elion, G.B., Mechanism of action and selectivity of acyclovir. The American Journal of Medicine 73 (1982), 7–13.
30. Enria, D.A., Maiztegui, J.I., Antiviral treatment of argentine hemorrhagic fever. Antiviral Research 23 (1994), 23–31.
31. Escribano-Romero, E., Jiménez de Oya, N., Domingo, E., Saiz, J.C., Extinction of West Nile virus by favipiravir through lethal mutagenesis. Antimicrobial Agents and Chemotherapy, 61(11), 2017 Oct 24, 10.1128/AAC.01400-17 (Print 2017 Nov; pii: e01400-17).
32. EuroWHO, Past pandemics. Influenza, 2019 http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/pandemic-influenza/past-pandemics.
33. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research 100 (2013), 446–454.
34. Furuta, Y., Komeno, T., Nakamura, T., Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 93 (2017), 449–463.
35. Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Shiraki, K., In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial Agents and Chemotherapy 46 (2002), 977–981.
36. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Shiraki, K., Mechanism of action of T-705 against influenza virus. Antimicrobial Agents and Chemotherapy 49 (2005), 981–986.
37. Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D.F., Barnard, D.L., Morrey, J.D., T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research 82 (2009), 95–102.
38. Goldhill, D.H., Langat, P., Xie, H., Galiano, M., Miah, S., Kellam, P., Barclay, W.S., Determining the mutation Bias of Favipiravir in influenza virus using next-generation sequencing. Journal of Virology 93 (2019), e01217–e01218.
39. Goldhill, D.H., Te Velthuis, A.J.W., Fletcher, R.A., Langat, P., Zambon, M., Lackenby, A., Barclay, W.S., The mechanism of resistance to favipiravir in influenza. Proceedings of the National Academy of Sciences of the United States of America 115 (2018), 11613–11618.
40. Gowen, B.B., Juelich, T.L., Sefing, E.J., Brasel, T., Smith, J.K., Zhang, L., Freiberg, A.N., Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a Guinea pig model of argentine hemorrhagic fever. PLoS Neglected Tropical Diseases, 7, 2013, e2614.
41. Gowen, B.B., Westover, J.B., Miao, J., Van Wettere, A.J., Rigas, J.D., Hickerson, B.T., Wang, Z., Modeling severe fever with thrombocytopenia syndrome virus infection in Golden Syrian hamsters: Importance of STAT2 in preventing disease and effective treatment with Favipiravir. Journal of Virology, 91, 2017 e01942–16.
42. Gowen, B.B., Westover, J.B., Sefing, E.J., Van Wettere, A.J., Bailey, K.W., Wandersee, L., Furuta, Y., Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antiviral Research 145 (2017), 131–135.
43. Gowen, B.B., Wong, M.H., Jung, K.H., Sanders, A.B., Mendenhall, M., Bailey, K.W., Sidwell, R.W., In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrobial Agents and Chemotherapy 51 (2007), 3168–3176.
44. Gowen, B.B., Wong, M.H., Jung, K.H., Smee, D.F., Morrey, J.D., Furuta, Y., Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Research 86 (2010), 121–127.
45. Gubareva, L.V., Fry, A.M., Baloxavir and treatment-emergent resistance: Public health insights and next steps. The Journal of Infectious Diseases 221 (2019), 337–339.
46. Guillot, L., Le Goffic, R., Bloch, S., Escriou, N., Akira, S., Chignard, M., Si-Tahar, M., Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. The Journal of Biological Chemistry 280 (2005), 5571–5580.
47. Hama, Y., Kurokawa, M., Imakita, M., Yoshida, Y., Shimizu, T., Watanabe, W., Shiraki, K., Interleukin 12 is a primary cytokine responding to influenza virus infection in the respiratory tract of mice. Acta Virologica 53 (2009), 233–240.
48. Hawman, D.W., Haddock, E., Meade-White, K., Williamson, B., Hanley, P.W., Rosenke, K., Feldmann, H., Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antiviral Research 157 (2018), 18–26.
49. Hayden, F.G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M.D., Hurt, A.C., Baloxavir Marboxil Investigators, G., Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. The New England Journal of Medicine 379 (2018), 913–923.
50. Hirotsu, N., Sakaguchi, H., Sato, C., Ishibashi, T., Baba, K., Omoto, S., Watanabe, A., Baloxavir marboxil in Japanese pediatric patients with influenza: Safety and clinical and virologic outcomes. Clin Infect Dis., 2019, ciz908, 10.1093/cid/ciz908.
51. Hurt, A.C., Ernest, J., Deng, Y.M., Iannello, P., Besselaar, T.G., Birch, C., Barr, I.G., Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Research 83 (2009), 90–93.
52. Ida, M., Kageyama, S., Sato, H., Kamiyama, T., Toyomoto, T., Ozaki, T., Shiraki, K., Characterization of acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during acyclovir therapy. Journal of Dermatological Science 23 (2000), 63–72.
53. Ida, M., Kageyama, S., Sato, H., Kamiyama, T., Yamamura, J., Kurokawa, M., Shiraki, K., Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Research 40 (1999), 155–166.
54. Jacobs, M., Aarons, E., Bhagani, S., Buchanan, R., Cropley, I., Hopkins, S., Rodger, A., Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: A case-series of health-care workers. The Lancet Infectious Diseases 15 (2015), 1300–1304.
55. Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One, 8, 2013, e68347.
56. Jochmans, D., van Nieuwkoop, S., Smits, S.L., Neyts, J., Fouchier, R.A., van den Hoogen, B.G., Antiviral activity of Favipiravir (T-705) against a broad range of Paramyxoviruses in vitro and against human Metapneumovirus in hamsters. Antimicrobial Agents and Chemotherapy 60 (2016), 4620–4629.
57. Julander, J.G., Shafer, K., Smee, D.F., Morrey, J.D., Furuta, Y., Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrobial Agents and Chemotherapy 53 (2009), 202–209.
58. Julander, J.G., Smee, D.F., Morrey, J.D., Furuta, Y., Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Research 82 (2009), 169–171.
59. Kamiyama, T., Kurokawa, M., Shiraki, K., Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. The Journal of General Virology 82 (2001), 2761–2765.
60. Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Kawaoka, Y., Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 364 (2004), 759–765.
61. Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., Le, Q.M., Kawaoka, Y., T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 107 (2010), 882–887.
62. Ku, A.S., Chan, L.T., The first case of H5N1 avian influenza infection in a human with complications of adult respiratory distress syndrome and Reye's syndrome. Journal of Paediatrics and Child Health 35 (1999), 207–209.
63. Kuhar, D.T., Henderson, D.K., Struble, K.A., Heneine, W., Thomas, V., Cheever, L.W., US Public Health Service Working Group, Updated US public health service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control and Hospital Epidemiology 34 (2013), 875–892.
64. Kuramoto, T., Daikoku, T., Yoshida, Y., Takemoto, M., Oshima, K., Eizuru, Y., Shiraki, K., Novel anti-cytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. The Journal of Pharmacology and Experimental Therapeutics 333 (2010), 1–6.
65. Kurokawa, M., Brown, J., Kagawa, Y., Shiraki, K., Cytokine-regulatory activity and therapeutic efficacy of cinnamyl derivatives in endotoxin shock. European Journal of Pharmacology 474 (2003), 283–293.
66. Kurokawa, M., Imakita, M., Kumeda, C.A., Shiraki, K., Cascade of fever production in mice infected with influenza virus. Journal of Medical Virology 50 (1996), 152–158.
67. Kurokawa, M., Imakita, M., Kumeda, C.A., Yukawa, T.A., Shiraki, K., Kakkon-to suppressed interleukin 1α production responsive to interferon and alleviated influenza infection in mice. J Traditional Med 13 (1996), 201–209.
68. Kurokawa, M., Kumeda, C.A., Yamamura, J., Kamiyama, T., Shiraki, K., Antipyretic activity of cinnamyl derivatives and related compounds in influenza virus-infected mice. European Journal of Pharmacology 348 (1998), 45–51.
69. Kurokawa, M., Tsurita, M., Brown, J., Fukuda, Y., Shiraki, K., Effect of interleukin-12 level augmented by Kakkon-to, a herbal medicine, on the early stage of influenza infection in mice. Antiviral Research 56 (2002), 183–188.
70. Kurokawa, M., Watanabe, W., Shimizu, T., Sawamura, R., Shiraki, K., Modulation of cytokine production by 7-hydroxycoumarin in vitro and its efficacy against influenza infection in mice. Antiviral Research 85 (2010), 373–380.
71. Kurokawa, M., Yamamura, J., Li, Z., Sato, H., Hitomi, N., Tatsumi, Y., Shiraki, K., Antipyretic activity of gingyo-san, a traditional medicine, in influenza virus-infected mice. Chem Pharm Bull (Tokyo) 46 (1998), 1444–1447.
72. Kurosaki, K., Miwa, N., Yoshida, Y., Kurokawa, M., Kurimoto, M., Endo, S., Shiraki, K., Therapeutic basis of vidarabine on adenovirus-induced haemorrhagic cystitis. Antiviral Chemistry & Chemotherapy 15 (2004), 281–285.
73. Lai, S., Qin, Y., Cowling, B.J., Ren, X., Wardrop, N.A., Gilbert, M., Yu, H., Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: A systematic review of individual case data. The Lancet Infectious Diseases 16 (2016), e108–e118.
74. Lee, K., Kolb, A.W., Sverchkov, Y., Cuellar, J.A., Craven, M., Brandt, C.R., Recombination analysis of herpes simplex virus 1 reveals a Bias toward GC content and the inverted repeat regions. Journal of Virology 89 (2015), 7214–7223.
75. Li, Q., Zhou, L., Zhou, M., Chen, Z., Li, F., Wu, H., Feng, Z., Epidemiology of human infections with avian influenza A(H7N9) virus in China. The New England Journal of Medicine 370 (2014), 520–532.
76. Lina, B., Boucher, C., Osterhaus, A., Monto, A.S., Schutten, M., Whitley, R.J., Nguyen-Van-Tam, J.S., Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza and Other Respiratory Viruses 12 (2018), 267–278.
77. Maurer, J.R., Frost, A.E., Estenne, M., Higenbottam, T., Glanville, A.R., International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 66 (1998), 951–956.
78. McGeoch, D.J., Dolan, A., Ralph, A.C., Toward a comprehensive phylogeny for mammalian and avian herpesviruses. Journal of Virology 74 (2000), 10401–10406.
79. Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Zambon, M., Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerging Infectious Diseases 15 (2009), 552–560.
80. Memoli, M.J., Athota, R., Reed, S., Czajkowski, L., Bristol, T., Proudfoot, K., Taubenberger, J.K., The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clinical Infectious Diseases 58 (2014), 214–224.
81. Mendenhall, M., Russell, A., Smee, D.F., Hall, J.O., Skirpstunas, R., Furuta, Y., Gowen, B.B., Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Neglected Tropical Diseases, 5, 2011, e1342.
82. Miwa, N., Kurosaki, K., Yoshida, Y., Kurokawa, M., Saito, S., Shiraki, K., Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus. Antiviral Research 65 (2005), 49–55.
83. Mori, H., Shiraki, K., Kato, T., Hayakawa, Y., Yamanishi, K., Takahashi, M., Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus. Intervirology 29 (1988), 301–310.
84. Morrey, J.D., Taro, B.S., Siddharthan, V., Wang, H., Smee, D.F., Christensen, A.J., Furuta, Y., Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Research 80 (2008), 377–379.
85. Naesens, L., Guddat, L.W., Keough, D.T., van Kuilenburg, A.B., Meijer, J., Vande Voorde, J., Balzarini, J., Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Molecular Pharmacology 84 (2013), 615–629.
86. National Kidney Foundation, Hemodialysis. 2019, National Kidney Foundation, New York https://www.kidney.org/atoz/content/hemodialysis.
87. Oestereich, L., Ludtke, A., Wurr, S., Rieger, T., Munoz-Fontela, C., Gunther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research 105 (2014), 17–21.
88. Oestereich, L., Rieger, T., Ludtke, A., Ruibal, P., Wurr, S., Pallasch, E., Gunther, S., Efficacy of Favipiravir alone and in combination with ribavirin in a lethal, Immunocompetent mouse model of Lassa fever. The Journal of Infectious Diseases 213 (2016), 934–938.
89. Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Gunther, S., Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Neglected Tropical Diseases, 8, 2014, e2804.
90. Omoto, S., Speranzini, V., Hashimoto, T., Noshi, T., Yamaguchi, H., Kawai, M., Cusack, S., Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Scientific Reports, 8, 2018, 9633.
91. Philpott, D.C.E., Nolan, M.S., Evert, N., Mayes, B., Hesalroad, D., Fonken, E., Murray, K.O., Acute and delayed deaths after West Nile virus infection, Texas, USA, 2002-2012. Emerging Infectious Diseases 25 (2019), 256–264.
92. Pomfret, E.A., Pomposelli, J.J., Jenkins, R.L., Live donor liver transplantation. Journal of Hepatology 34 (2001), 613–624.
93. Poux, C., Dondalska, A., Bergenstrahle, J., Palsson, S., Contreras, V., Arasa, C., Spetz, A.L., A single-stranded oligonucleotide inhibits toll-like receptor 3 activation and reduces influenza A (H1N1) infection. Frontiers in Immunology, 10, 2019, 2161.
94. Raabe, V.N., Kann, G., Ribner, B.S., Morales, A., Varkey, J.B., Mehta, A.K., Emory Serious Communicable Diseases, U., Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clinical Infectious Diseases 65 (2017), 855–859.
95. Renault, P., Josseran, L., Pierre, V., Chikungunya-related fatality rates, Mauritius, India, and Reunion Island. Emerging Infectious Diseases, 14, 2008, 1327.
96. Rocha-Pereira, J., Jochmans, D., Dallmeier, K., Leyssen, P., Nascimento, M.S., Neyts, J., Favipiravir (T-705) inhibits in vitro norovirus replication. Biochemical and Biophysical Research Communications 424 (2012), 777–780.
97. Ruis, C., Brown, L.K., Roy, S., Atkinson, C., Williams, R., Burns, S.O., Lowe, D.M., Mutagenesis in norovirus in response to Favipiravir treatment. The New England Journal of Medicine 379 (2018), 2173–2176.
98. Safronetz, D., Falzarano, D., Scott, D.P., Furuta, Y., Feldmann, H., Gowen, B.B., Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrobial Agents and Chemotherapy 57 (2013), 4673–4680.
99. Safronetz, D., Rosenke, K., Westover, J.B., Martellaro, C., Okumura, A., Furuta, Y., Gowen, B.B., The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset. Scientific Reports, 5, 2015, 14775.
100. Sangawa, H., Komeno, T., Nishikawa, H., Yoshida, A., Takahashi, K., Nomura, N., Furuta, Y., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrobial Agents and Chemotherapy 57 (2013), 5202–5208.
101. Scharton, D., Bailey, K.W., Vest, Z., Westover, J.B., Kumaki, Y., Van Wettere, A., Gowen, B.B., Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Research 104 (2014), 84–92.
102. Shimada, Y., Suzuki, M., Shirasaki, F., Saito, E., Sogo, K., Hasegawa, M., Shiraki, K., Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus. Journal of Medical Virology 79 (2007), 1731–1740.
103. Shinya, K., Ebina, M., Yamada, S., Ono, M., Kasai, N., Kawaoka, Y., Avian flu: Influenza virus receptors in the human airway. Nature 440 (2006), 435–436.
104. Shiraki, K., Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster. Drugs Today (Barc) 53 (2017), 573–584.
105. Shiraki, K., Antiviral drugs against Alphaherpesvirus. Advances in Experimental Medicine and Biology 1045 (2018), 103–122.
106. Shiraki, K., Ogino, T., Yamanishi, K., Takahashi, M., Isolation of drug-resistant mutants of varicella-zoster virus - cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine. Biken Journal 26 (1983), 17–23.
107. Shiraki, K., Ogino, T., Yamanishi, K., Takahashi, M., Immunochemical characterization of pyrimidine kinase induced by varicella-zoster virus. The Journal of General Virology 66:Pt 2 (1985), 221–229.
108. Sidwell, R.W., Barnard, D.L., Day, C.W., Smee, D.F., Bailey, K.W., Wong, M.H., Furuta, Y., Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial Agents and Chemotherapy 51 (2007), 845–851.
109. Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.B., Beavogui, A.H., Baize, S., Group, J.S., Experimental treatment with Favipiravir for Ebola virus disease (the JIKI trial): A historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Medicine, 13, 2016, e1001967.
110. Smith, E.C., Blanc, H., Surdel, M.C., Vignuzzi, M., Denison, M.R., Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathogens, 9, 2013, e1003565.
111. Smither, S.J., Eastaugh, L.S., Steward, J.A., Nelson, M., Lenk, R.P., Lever, M.S., Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Research 104 (2014), 153–155.
112. Spickler, A.R., Eastern, Western and Venezuelan Equine Encephalomyelitis. 2017, The Center for Food Security and Public Health http://www.cfsph.iastate.edu/Factsheets/pdfs/easter_wester_venezuelan_equine_encephalomyelitis.pdf.
113. Takahashi, K., Furuta, Y., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Shiraki, K., In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antiviral Chemistry & Chemotherapy 14 (2003), 235–241.
114. Takashita, E., Ejima, M., Ogawa, R., Fujisaki, S., Neumann, G., Furuta, Y., Odagiri, T., Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Research 132 (2016), 170–177.
115. Takashita, E., Ichikawa, M., Morita, H., Ogawa, R., Fujisaki, S., Shirakura, M., Odagiri, T., Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to Baloxavir, Japan, February 2019. Emerging Infectious Diseases 25 (2019), 2008–2111.
116. Talarico, C.L., Phelps, W.C., Biron, K.K., Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. Journal of Virology 67 (1993), 1024–1033.
117. Tanaka, T., Kamiyama, T., Daikoku, T., Takahashi, K., Nomura, N., Kurokawa, M., Shiraki, K., T-705 (Favipiravir) suppresses tumor necrosis factor alpha production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug. Acta Virologica 61 (2017), 48–55.
118. Tani, H., Fukuma, A., Fukushi, S., Taniguchi, S., Yoshikawa, T., Iwata-Yoshikawa, N., Saijo, M., Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere, 1(1), 2016 Jan-Feb. e00061–15.
119. Tsurita, M., Kurokawa, M., Imakita, M., Fukuda, Y., Watanabe, Y., Shiraki, K., Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. The Journal of Pharmacology and Experimental Therapeutics 298 (2001), 362–368.
120. Uehara, T., Hayden, F.G., Kawaguchi, K., Omoto, S., Hurt, A.C., De Jong, M.D., Kida, H., (2019). Treatment-emergent influenza variant viruses with reduced Baloxavir susceptibility: Impact on clinical and Virologic outcomes in uncomplicated influenza. The Journal of Infectious Diseases 221:3 (2020 Jan 14), 346–355.
121. Vanderlinden, E., Vrancken, B., Van Houdt, J., Rajwanshi, V.K., Gillemot, S., Andrei, G., Naesens, L., Distinct effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrobial Agents and Chemotherapy 60 (2016), 6679–6691.
122. Vignuzzi, M., Stone, J.K., Andino, R., Ribavirin and lethal mutagenesis of poliovirus: Molecular mechanisms, resistance and biological implications. Virus Research 107 (2005), 173–181.
123. Wang, Y., Fan, G., Salam, A., Horby, P., Hayden, F.G., Chen, C., Network, C. A.-C., Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis, 2019, jiz656, 10.1093/infdis/jiz656.
124. Westover, J.B., Sefing, E.J., Bailey, K.W., Van Wettere, A.J., Jung, K.H., Dagley, A., Gowen, B.B., Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Research 126 (2016), 62–68.
125. Wheeler, L.J., Rajagopal, I., Mathews, C.K., Stimulation of mutagenesis by proportional deoxyribonucleoside triphosphate accumulation in Escherichia coli. DNA Repair (Amst) 4 (2005), 1450–1456.
126. Whitley, R.J., Hayden, F.G., Reisinger, K.S., Young, N., Dutkowski, R., Ipe, D., Ward, P., Oral oseltamivir treatment of influenza in children. The Pediatric Infectious Disease Journal 20 (2001), 127–133.
127. Wong, J.P., Christopher, M.E., Viswanathan, S., Karpoff, N., Dai, X., Das, D., Salazar, A.M., Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27 (2009), 3481–3483.
128. Yamada, K., Noguchi, K., Komeno, T., Furuta, Y., Nishizono, A., Efficacy of Favipiravir (T-705) in rabies Postexposure prophylaxis. The Journal of Infectious Diseases 213 (2015), 1253–1261.
129. Yang, C.W., Chen, S.M., A comparative study of human TLR 7/8 stimulatory trimer compositions in influenza A viral genomes. PLoS One, 7, 2012, e30751.
130. Yasukawa, M., Clinical study of favipiravir for patients with severe fever with thrombocytopenia syndrome. In UMIN000022398 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033194, 2016.
131. Zhu, W., Zhang, Z., He, S., Wong, G., Banadyga, L., Qiu, X., Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Antiviral Research 151 (2018), 39–49.